Lumosa Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Lumosa Therapeutics wird ein Gewinn- und Umsatzwachstum von 119.4% bzw. 146.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 119.7% pro Jahr wachsen soll.

Wichtige Informationen

111.0%

Wachstumsrate der Gewinne

111.3%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	40.8%
Wachstumsrate der Einnahmen	146.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	19 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Lumosa Therapeutics'(GTSM:6535) Share Price Is Down 47% Over The Past Five Years.

Mar 10

We're Hopeful That Lumosa Therapeutics (GTSM:6535) Will Use Its Cash Wisely

Nov 24

Gewinn- und Umsatzwachstumsprognosen

TPEX:6535 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (TWD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	816	239	478	73	2
12/31/2024	59	-437	-471	-464	2
3/31/2024	53	-499	-346	-331	N/A
12/31/2023	57	-238	-343	-328	N/A
9/30/2023	53	-86	-306	-293	N/A
6/30/2023	41	-121	-329	-327	N/A
3/31/2023	32	-165	-306	-303	N/A
12/31/2022	27	-495	-303	-300	N/A
9/30/2022	22	-862	-439	-437	N/A
6/30/2022	18	-239	-422	-420	N/A
3/31/2022	18	-156	-437	-436	N/A
12/31/2021	17	96	-453	-453	N/A
9/30/2021	21	339	-360	-359	N/A
6/30/2021	22	-177	-379	-379	N/A
3/31/2021	22	-144	-368	-367	N/A
12/31/2020	22	-323	-130	-129	N/A
9/30/2020	168	-333	-269	-268	N/A
6/30/2020	169	-364	-238	-238	N/A
3/31/2020	167	-272	-180	-196	N/A
12/31/2019	172	-241	-363	-380	N/A
9/30/2019	30	-134	-138	-150	N/A
6/30/2019	61	-68	-96	-108	N/A
3/31/2019	59	-114	-85	-80	N/A
12/31/2018	61	-50	-87	-82	N/A
9/30/2018	45	-109	-99	-98	N/A
6/30/2018	15	-146	-96	-95	N/A
3/31/2018	19	-183	-78	-76	N/A
12/31/2017	35	-213	N/A	-68	N/A
9/30/2017	32	-225	N/A	-116	N/A
6/30/2017	30	-248	N/A	-95	N/A
3/31/2017	38	-223	N/A	-136	N/A
12/31/2016	12	-230	N/A	-143	N/A
9/30/2016	22	-204	N/A	-98	N/A
6/30/2016	22	-231	N/A	-148	N/A
3/31/2016	10	-247	N/A	-141	N/A
12/31/2015	10	-235	N/A	-138	N/A
9/30/2015	N/A	-271	N/A	-155	N/A
6/30/2015	N/A	-239	N/A	-126	N/A
3/31/2015	N/A	-189	N/A	-99	N/A
12/31/2014	N/A	-157	N/A	-76	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 6535 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 6535 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 6535 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 6535Die Einnahmen des Unternehmens (146.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt TW (11.6% pro Jahr).

Hohe Wachstumseinnahmen: 6535Die Einnahmen des Unternehmens (146.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 6535 in 3 Jahren voraussichtlich hoch sein wird

Lumosa Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Now 22% overvalued after recent price rise

Less than half of directors are independent

Less than half of directors are independent

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Lumosa Therapeutics Co., Ltd. announced that it expects to receive TWD 50 million in funding

Lumosa Therapeutics Co., Ltd. Announces the Change of Chairperson

Lumosa Therapeutics Co., Ltd. to Report Q1, 2024 Results on May 14, 2024

Full year 2023 earnings released: NT$1.47 loss per share (vs NT$3.05 loss in FY 2022)

Lumosa Therapeutics Co., Ltd., Annual General Meeting, May 02, 2024

Lumosa Therapeutics and CHI Memorial Announce New Study for Acute Stroke

New minor risk - Share price stability

Lumosa Therapeutics Co., Ltd. Receives Approval to Initiate Phase 2, Multiple-Dose Study of Its LT3001

Second quarter 2023 earnings released: NT$0.92 loss per share (vs NT$1.20 loss in 2Q 2022)

Full year 2022 earnings released: NT$3.05 loss per share (vs NT$0.64 profit in FY 2021)

Less than half of directors are independent

Second quarter 2022 earnings released: NT$1.20 loss per share (vs NT$0.74 loss in 2Q 2021)

First quarter 2022 earnings released: NT$1.14 loss per share (vs NT$0.46 profit in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Lumosa Therapeutics Co., Ltd., Annual General Meeting, May 24, 2022

Lumosa Therapeutics Announces US FDA Clearance of IND Application for a Phase 2 Multi-Dose Study of LT3001 in Patients with Acute Ischemic Stroke

Lumosa Therapeutics Co., Ltd. Announces Lt3001 Granted Fast TrackDesignation for the Treatment of Acute Ischemic Stroke Toexpedite the Drug Registration Process with the US FDA

Lumosa Announces the Completion of the Phase 1Clinical Trial on the Pharmacokinetics of Multiple Dosesand the Drug-Drug Interaction for LT3001

Lumosa Receives an Notification from AMed Regarding the Receipt of an Import Permit from Thai Food and Drug Administration for Naldebain

Lumosa Therapeutics Co., Ltd. announced that it has received TWD 330 million in funding

Investor sentiment improved over the past week

Second quarter 2021 earnings released: NT$0.74 loss per share (vs NT$0.67 loss in 2Q 2020)

Lumosa Therapeutics Co., Ltd. Announces Positive Results from LT3001 Phase 2a Clinical Trial in Acute Ischemic Stroke

Lumosa Therapeutics Co., Ltd. Announces the Granting of the Formulation Patent for LT1001

Patent of Lumosa’s LT5001 Product Granted by Taiwan Intellectual Property Office

First quarter 2021 earnings released: EPS NT$0.46 (vs NT$0.95 loss in 1Q 2020)

Chief Internal Auditor has left the company

Full year 2020 earnings released: NT$2.67 loss per share (vs NT$2.05 loss in FY 2019)

Lumosa Therapeutics Co., Ltd. announced that it expects to receive TWD 99.992 million in funding from Far Glory Life Insurance Co., Ltd., Asset Management Arm

Lumosa Therapeutics Co., Ltd. Announces Resignation of Ya-Ting Hsu as Chief Internal Auditor, Effective March 31, 2021

Lumosa Therapeutics'(GTSM:6535) Share Price Is Down 47% Over The Past Five Years.

Lumosa Therapeutics Co., Ltd. Announces Approval by Korean Intellectual Property Office and European Patent Office for Lumosa's LT3001, A New Drug for Acute Ischemic Stroke

New 90-day low: NT$33.45

Lumosa Therapeutics Receives Market Approval of LT001 from Singapore's Health Science Agency

Lumosa Therapeutics Co., Ltd. to Commence A Multi-Dose,Drug-Drug-Interaction, Phase I Trial of LT3001 for AIS

Lumosa Announces Completion of Enrollment Inphase 2 Clinical Trial of Its LT3001 for Thetreatment of Acute Ischemic Stroke

Lumosa Therapeutics Co., Ltd. announced that it has received TWD 855.5 million in funding from Center Laboratories, Inc. and other investors

We're Hopeful That Lumosa Therapeutics (GTSM:6535) Will Use Its Cash Wisely

Third quarter 2020 earnings released: NT$0.40 loss per share

New 90-day low: NT$33.90

Lumosa and AMed Sign a Supplementary Licensing Agreement for the Licensing of Extended-Release Analgesic Injection in Southeast Asia

First half earnings released

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken